Oncotelic Therapeutics, Inc. (OTLC) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
29397 AGOURA RD. AGUORA HILLS, CA 91301 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 170 | 241 | 569 | 474 | 82 | 629 | |||
| Cash and cash equivalent | 170 | 241 | 569 | 474 | 82 | 629 | |||
| Receivables | 19 | 20 | 20 | 20 | 150 | ||||
| Other undisclosed current assets | 82 | 42 | 39 | 122 | 41 | 170 | |||
| Total current assets: | 272 | 303 | 627 | 616 | 273 | 799 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 1,102 | 1,102 | 990 | 1,010 | 48 | ||||
| Intangible assets, net (including goodwill) | 5,988 | 12,880 | 21,884 | 21,936 | 21,987 | ||||
| Goodwill | 5,988 | 12,071 | 21,062 | 21,062 | 21,062 | ||||
| Intangible assets, net (excluding goodwill) | 809 | 822 | 873 | 925 | |||||
| Other undisclosed noncurrent assets | 22,653 | 21,832 | 112 | 102 | 1,377 | ||||
| Total noncurrent assets: | 29,743 | 35,814 | 22,986 | 23,048 | 23,412 | ||||
| TOTAL ASSETS: | 30,015 | 36,117 | 23,613 | 23,663 | 23,685 | 799 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 2,437 | 2,511 | 3,093 | 2,736 | 2,055 | 1,134 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 24 | |||||
| Accounts payable | 1,736 | 1,928 | 1,937 | 1,793 | 915 | ||||
| Accrued liabilities | 775 | 1,165 | 798 | 262 | 195 | ||||
| Other undisclosed accounts payable and accrued liabilities | 2,437 | ||||||||
| Debt | 9,832 | 730 | 8,449 | 4,382 | 1,105 | ||||
| Derivative instruments and hedges, liabilities | 423 | 198 | 340 | 777 | 541 | ||||
| Business combination, contingent consideration, liability | 2,625 | 2,625 | 2,625 | 2,625 | |||||
| Due to related parties | ✕ | ✕ | 10,424 | 403 | 392 | 602 | |||
| Other undisclosed current liabilities | 1,187 | 435 | 545 | 271 | 2,481 | 27 | |||
| Total current liabilities: | 16,505 | 16,923 | 15,455 | 11,182 | 6,783 | 1,161 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 1,898 | ||||||||
| Long-term debt, excluding current maturities | 1,898 | ||||||||
| Other undisclosed noncurrent liabilities | |||||||||
| Total noncurrent liabilities: | 1,898 | ||||||||
| Total liabilities: | 18,403 | 16,923 | 15,455 | 11,182 | 6,783 | 1,161 | |||
| Equity | |||||||||
| Equity, attributable to parent | 12,130 | 19,409 | 7,956 | 11,772 | 16,902 | (362) | |||
| Preferred stock | 3 | 3 | |||||||
| Common stock | 3,992 | 3,918 | 3,753 | 906 | 841 | 414 | |||
| Additional paid in capital | 41,655 | 41,417 | 35,224 | 32,493 | 28,186 | 294,236 | |||
| Accumulated deficit | (33,517) | (25,926) | (31,021) | (21,630) | (12,127) | (295,012) | |||
| Equity, attributable to noncontrolling interest | (519) | (216) | 203 | 709 | |||||
| Total equity: | 11,612 | 19,193 | 8,158 | 12,481 | 16,902 | (362) | |||
| TOTAL LIABILITIES AND EQUITY: | 30,015 | 36,117 | 23,613 | 23,663 | 23,685 | 799 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 70 | 1,741 | ||||||
| Gross profit: | 70 | 1,741 | ||||||
| Operating expenses | (6,718) | (9,722) | (9,126) | (9,326) | (4,311) | (3,002) | ||
| Operating loss: | (6,648) | (9,722) | (9,126) | (7,585) | (4,311) | (3,002) | ||
| Nonoperating income (expense) | (1,558) | 14,398 | (1,391) | (2,387) | (2,327) | 15 | ||
| Investment income, nonoperating | 13 | 0 | 16 | |||||
| Debt instrument, convertible, beneficial conversion feature | 571 | 970 | 724 | |||||
| Interest and debt expense | (373) | (258) | (2,030) | (2,342) | (750) | |||
| Income (loss) from continuing operations: | (8,579) | 4,419 | (12,548) | (12,314) | (7,388) | (2,987) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (12,548) | (12,314) | (7,388) | (2,987) | |
| Other undisclosed net income | 373 | 258 | 2,030 | 2,342 | 250 | |||
| Net income (loss): | (8,206) | 4,677 | (10,517) | (9,972) | (7,388) | (2,737) | ||
| Net income (loss) attributable to noncontrolling interest | 303 | 418 | 1,126 | (469) | ||||
| Other undisclosed net income attributable to parent | 938 | 750 | ||||||
| Net income (loss) available to common stockholders, diluted: | (7,903) | 5,095 | (9,391) | (9,503) | (6,638) | (2,737) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (8,206) | 4,677 | (10,517) | (9,972) | (7,388) | (2,737) | ||
| Comprehensive income (loss): | (8,206) | 4,677 | (10,517) | (9,972) | (7,388) | (2,737) | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 303 | 418 | 1,126 | (469) | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | (7,903) | 5,095 | (9,391) | (10,441) | (7,388) | (2,737) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.